Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study.

Navarro-González JF, Donate-Correa J, Méndez ML, de Fuentes MM, García-Pérez J, Mora-Fernández C.

J Clin Pharmacol. 2013 Apr;53(4):421-6. doi: 10.1002/jcph.19. Epub 2013 Feb 20.

PMID:
23426718
[PubMed - indexed for MEDLINE]
3.

Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.

Goldenberg MM.

Clin Ther. 1999 Mar;21(3):432-41. Review.

PMID:
10321413
[PubMed - indexed for MEDLINE]
4.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
[PubMed - indexed for MEDLINE]
5.

Cytokine production in patients on dialysis.

Pereira BJ.

Blood Purif. 1995;13(3-4):135-46. Review.

PMID:
7619385
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk